Month: September 2020

Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) — Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in ruling on September 22, 2020, the German Federal Supreme Court overturned a decision by the Cologne Higher Regional Court dated November 15, 2018, which was directed against the Company. The overturned ruling of the Cologne Higher Regional Court concerned an action for rescission and annulment brought by the shareholder Deutsche Balaton AG against certain resolutions of the Annual General Meeting held on May 24, 2017. The matter has now been referred back to the Cologne Higher Regional Court for retrial and decision. The reasons for the ruling of the Federal Supreme Court are currently not available to the Company.Context and chronology...

Eurobio Scientific launches a first rapid diagnostic testfor the detection of the SARS CoV-2 virus antigenParis, September 22,  2020 –6:00 pmEurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life sciences, today announces the launch of a first rapid diagnostic test for the detection of the SARS CoV-2 virus antigen . This test, Sofia® SARS Antigen developed by its American partner Quidel, is complementary to PCR tests which remain the performance gold standard in terms of detection of the virus responsible for COVID-19. It is already CE marked and immediately available for sale.As part of the current campaign to detect the presence of the SARS CoV-2 virus in patients, the number of tests performed in France has become of such magnitude (more than 1 million tests per week)...

Eurobio Scientific lance un premier test de diagnostic rapide permettant la recherche de l’antigène du virus SARS CoV-2.Paris, le 22 septembre 2020 –18h00Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro et les sciences de la vie, annonce aujourd’hui le lancement d’un premier test de diagnostic rapide permettant la recherche de l’antigène du virus SARS CoV-2.  Ce test, Sofia® SARS Antigen, développé par son partenaire américain Quidel, est complémentaire des tests de PCR qui restent la référence en termes de performances de détection du virus responsable de COVID-19. Il est déjà marqué CE et disponible immédiatement à la vente.Dans le cadre de la campagne actuelle de détection de la présence du virus SARS CoV-2 chez les patients, le nombre de tests réalisé est devenu...

Article 8:6 of the Royal Decree of 29 April 2019, which implements the new Belgian Code of Companies and Associations as of 01/01/2020, stipulates that any disposal of own shares has to be made public.In application of this Article, Umicore declares that following the exercise of stock options by its employees within the framework of the Umicore Incentive Stock Option Plan, it has since 01/01/2020 disposed of Umicore shares OTC in view of deliveries of these shares to the relevant employees. Umicore also disposed of own shares in the context of share grants to the Management and Supervisory Board.Please find below the overview of the transactions for the period 14/09/2020 – 18/09/2020:The complete overview of all disposals of own shares by Umicore since 01/01/2020 can be found here.For more informationInvestor RelationsEvelien Goovaerts...

L’article 8:6 de l’Arrêté Royal du 29 avril 2019, portant exécution du nouveau Code des sociétés et association à partir du 1er janvier 2020, stipule que toute aliénation d’actions propres doit être rendue publique.En vertu de cet article, Umicore déclare que suite à des exercices d’options par son personnel dans le cadre de la rémunération via options sur actions d’Umicore (Umicore Incentive Stock Option Plan), elle a, depuis le 1er janvier 2020, aliéné des actions Umicore hors bourse (OTC) en vue des livraisons de ces actions aux membres du personnel concernés. Umicore a également aliéné des actions propres pour satisfaire à des octrois d’actions aux membres du Conseil de direction et du Conseil de surveillance.Voici un aperçu des transactions effectuées entre le 14/09/2020 et le 18/09/2020:Un aperçu reprenant toutes les aliénations...

Artikel 8:6 van het Koninklijk Besluit van 29 april 2019 tot uitvoering van het nieuwe Wetboek van vennootschappen en verenigingen, bepaalt dat elke vervreemding van eigen aandelen publiek gemaakt dient te worden sinds 01/01/2020.In uitvoering van dit Artikel, maakt Umicore bekend dat ingevolge uitoefeningen van opties door haar personeel in het kader van het Umicore Incentive Stock Option Plan, zij sinds 01/01/2020 buiten beurs (OTC) aandelen heeft vervreemd met het oog op het leveren van die aandelen aan het betrokken personeel. Umicore vervreemde ook eigen aandelen in het kader van aandelentoekenningen aan de directieraad en de raad van toezicht.Gelieve hieronder een overzicht te vinden van de transacties voor de periode 14/09/2020 – 18/09/2020:Het volledige overzicht van alle vervreemdingen van eigen aandelen door Umicore sinds 01/01/2020...

Quantum Genomics to receive up to $19 million in upfront and milestone payments plus double-digit royalties on salesOEP to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in South–East Asia, Australia and New ZealandPARIS and NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Orient EuroPharma (OEP) to develop and commercialize firibastat in South East Asia, Australia and New-Zealand. After its first partnership in Latin America, this...